Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

NCT05134532 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: regorafenib

Sponsor

CHA University

Collaborators

[object Object]